SMARCA1 and cancer: The exact frequency of SWI/SNF impairment cannot yet be estimated from mutational analyses alone, but based on currently available data, SWI/SNF is impaired in at least 16% via mutations – and possibly >90% – of cancers, if one considers all mechanisms of inactivation.